Importance of national context in the translation of personalised treatments for smoking cessation

Affiliations

¹ MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. Electronic address: jen.ware@bristol.ac.uk.
² MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.
³ MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; UK Centre for Tobacco and Alcohol Studies and School of Experimental Psychology, University of Bristol, Bristol, UK.

Comment

Jennifer J Ware et al. Lancet Respir Med. 2015 Feb.

. 2015 Feb;3(2):91-93.

doi: 10.1016/S2213-2600(14)70319-4. Epub 2015 Jan 12.

¹ MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK. Electronic address: jen.ware@bristol.ac.uk.
² MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; School of Social and Community Medicine, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.
³ MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; UK Centre for Tobacco and Alcohol Studies and School of Experimental Psychology, University of Bristol, Bristol, UK.

No abstract available

Comment on

Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial.
Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF; PGRN-PNAT Research Group. Lerman C, et al. Lancet Respir Med. 2015 Feb;3(2):131-138. doi: 10.1016/S2213-2600(14)70294-2. Epub 2015 Jan 12. Lancet Respir Med. 2015. PMID: 25588294 Free PMC article. Clinical Trial.